| Ceritinib studied in …STUDIED_INderived44 of 44show fewer |
|---|
| → studied in | NCT02393625Phase 1 · active not recruiting Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer · 44 trials list this drug (6 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02584933Phase 4 · active not recruiting Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study · 44 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02559778Phase 2 · recruiting Pediatric Precision Laboratory Advanced Neuroblastoma Therapy · 44 trials list this drug (6 active) | — | — | Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01964157Phase 2 · completed An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06813079Phase 2 · recruiting Using Tumor Models to Determine Treatments · 44 trials list this drug (6 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02321501Phase 1 · active not recruiting Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer · 44 trials list this drug (6 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03611738Phase 1 · active not recruiting Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC · 44 trials list this drug (6 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03784014Phase 3 · completed Molecular Profiling of Advanced Soft-tissue Sarcomas · 44 trials list this drug (6 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737994Phase 2 · terminated Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer · 44 trials list this drug (6 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05100134no longer available Managed Access Programs for LDK378, Ceritinib · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02780128Phase 1 · terminated Next Generation Personalized Neuroblastoma Therapy · 44 trials list this drug (6 active) | — | — | Malignant Neoplasm,Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03501368Phase 1 · completed Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma · 44 trials list this drug (6 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05834348completed A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01828112Phase 3 · completed LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01828099Phase 3 · completed LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03546894completed A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04647110completed Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. · 44 trials list this drug (6 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02513667Phase 2 · terminated Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma · 44 trials list this drug (6 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03087448Phase 1 · terminated Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02227940Phase 1 · completed Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer · 44 trials list this drug (6 active) | — | — | Malignant Solid Neoplasm,Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02299505Phase 1 · completed Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02186821Phase 2 · terminated Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) · 44 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02450903Phase 2 · completed LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01634763Phase 1 · completed Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) · 44 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01772797Phase 1 · completed Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02422589Phase 1 · completed A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors · 44 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02292550Phase 1 · completed Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer. · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02276027Phase 2 · completed A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer · 44 trials list this drug (6 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02605746early Phase 1 · completed Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis · 44 trials list this drug (6 active) | — | — | Glioblastoma,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01947608no longer available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01742286Phase 1 · completed Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) · 44 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02336451Phase 2 · completed A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges · 44 trials list this drug (6 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02587650Phase 2 · terminated Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma · 44 trials list this drug (6 active) | — | — | Cutaneous Melanoma,Invasive Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02465528Phase 2 · terminated Ceritinib Rare Indications Study in ALK+ Tumors · 44 trials list this drug (6 active) | — | — | Anaplastic Large Cell Lymphoma,Glioblastoma,Inflammatory Myofibroblastic Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02729961Phase 1/Phase 2 · withdrawn Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma · 44 trials list this drug (6 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive,Systemic Anaplastic Large Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02289144Phase 2 · withdrawn Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer · 44 trials list this drug (6 active) | — | — | Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01685138Phase 2 · completed LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01283516Phase 1 · completed A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02040870Phase 1/Phase 2 · completed LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03399487Phase 2 · unknown A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement · 44 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02374489Phase 2 · terminated A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma · 44 trials list this drug (6 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02638909Phase 2 · terminated Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies · 44 trials list this drug (6 active) | — | — | Cholangiocarcinoma,Colorectal Adenocarcinoma,Esophageal Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01685060Phase 2 · completed LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib · 44 trials list this drug (6 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02343679Phase 2 · withdrawn Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies · 44 trials list this drug (6 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |